Bambusa Therapeutics (BBTX) news
Recent news
Bambusa Therapeutics indicated to open at $15 each, IPO $16
Bambusa Therapeutics, a clinical-stage biotechnology company focused on immunology and inflammatory diseases, has set an initial public offering (IPO) price of $16 per share, within its previously announced range of $15 to $17. The company plans to offer 9.4 million shares, aiming to raise…
AInvest Wire · 4h agoBambusa Therapeutics indicated to open at $20 each, IPO $16
Bambusa Therapeutics, a clinical-stage biotechnology company focused on developing engineered cellular therapies for cancer and other serious diseases, has indicated an initial public offering (IPO) price of $16 per share and an opening price of $20 per share. This information reflects anticipated…
AInvest Wire · 4h agoBambusa said to allocate 90% of IPO shares to 15 investors
Bambusa Therapeutics, Inc. (BBTX) has announced that 90% of its initial public offering (IPO) shares will be allocated to 15 designated investors. The company plans to offer 9,375,000 shares in total, with the majority reserved for institutional or strategic investors . This allocation strategy is…
AInvest Wire · 5h agoBambusa Therapeutics upsized IPO prices at $16.00/shr
Bambusa Therapeutics, a biotechnology company developing therapies for immunological and inflammatory disorders, has priced its upsized initial public offering at $16.00 per share, according to its recent filing. The company is marketing 9.38 million shares as part of the offering, with the raised…
AInvest Wire · 19h agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.